A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignancies

Lijun Zhao; Shuhong Li; Xiaoyi Wei; Xuexiu Qi; Qiaoru Guo; Licai Shi; Ji-Shuai Zhang; Jun Li; Ze-Lin Liu; Zhi Guo; Hongyu Zhang; Jia Feng; Yuanyuan Shi; Suping Zhang; Yu J. Cao

doi:10.1093/procel/pwae034

Protein Cell ›› 2025, Vol. 16 ›› Issue (3) : 227 -232. DOI: 10.1093/procel/pwae034

LETTER

A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignancies

Author information +

History +

PDF (9132KB)

Cite this article

Download citation ▾

Lijun Zhao, Shuhong Li, Xiaoyi Wei, Xuexiu Qi, Qiaoru Guo, Licai Shi, Ji-Shuai Zhang, Jun Li, Ze-Lin Liu, Zhi Guo, Hongyu Zhang, Jia Feng, Yuanyuan Shi, Suping Zhang, Yu J. Cao. A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignancies. Protein Cell, 2025, 16(3): 227-232 DOI:10.1093/procel/pwae034

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	De Munter S , Ingels J , Goetgeluk G . Nanobody based dual specific CARs. Int J Mol Sci 2018; 19: 403.

[2]	Ereño-Orbea J , Liu X , Sicard T . Structural details of monoclonal antibody m971 recognition of the membrane-proximal domain of CD22. J Biol Chem 2021; 297: 100966.

[3]	Han L , Zhang J-S , Zhou J . Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma. Leukemia 2021; 35: 3002- 3006.

[4]	Mo F , Duan S , Jiang X . Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy. Signal Transduct Target Ther 2021; 6: 80.

[5]	Qin H , Ramakrishna S , Nguyen S . Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22. Mol Ther Oncolytics 2018; 11: 127- 137.

[6]	Schneider D , Xiong Y , Wu D . Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Sci Transl Med 2021; 13: eabc6401.

[7]	Schuster SJ , Bishop MR , Tam CS . JULIET Investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019; 380: 45- 56.

[8]	Shalabi H , Kraft IL , Wang H-W . Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. Haematologica 2018; 103: e215- e218.

[9]	Song M-K , Park B-B , Uhm J-E . Resistance mechanisms to CAR T-cell therapy and overcoming strategy in B-cell hematologic malignancies. Int J Mol Sci 2019; 20: 5010.

[10]	Spiegel JY , Patel S , Muffly L . CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med 2021; 27: 1419- 1431.

[11]	Wang F , Ekiert DC , Ahmad I . Reshaping antibody diversity. Cell 2013; 153: 1379- 1393.

[12]	Zanetti SR , Velasco-Hernandez T , Gutierrez-Agüera F . A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL. Mol Ther 2022; 30: 550- 563.